drugset
drugset / Trial / NCT05650528

QG101-23-0 Capsules SAD and MAD Study in Healthy Subjects

NCT05650528 ↗

Phase 1 Completed 78 enrolled Amckaus PTY LTD. Novotech (Australia) Pty Limited · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

The study will consist of three parts: a single-dose ascending (SAD) phase (Part A) enrolling a total of five \~ six cohorts of healthy participants, a multiple-dose ascending (MAD) phase (Part B) enrolling 3 cohorts of healthy participants, and a food effect study (Part C).

Timeline

Start
2023-03-21
Primary completion
2024-01-24
Completion
2024-02-26

Drugs

EvaluationDrugModalityDoseRoute
Subject QG101-23-0 Unknown — Oral

Indications

No indication recorded.